标题
Dapagliflozin suppresses glucagon signaling in rodent models of diabetes
作者
关键词
-
出版物
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Volume 114, Issue 25, Pages 6611-6616
出版商
Proceedings of the National Academy of Sciences
发表日期
2017-06-06
DOI
10.1073/pnas.1705845114
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
- (2016) André J. Scheen DIABETES & METABOLISM
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME
- (2016) André J. Scheen DIABETES RESEARCH AND CLINICAL PRACTICE
- Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
- (2016) Tushar Madaan et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus
- (2016) Abd A. Tahrani et al. Nature Reviews Endocrinology
- Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells
- (2016) Morten Gram Pedersen et al. Scientific Reports
- Experimental Diabetes Mellitus in Different Animal Models
- (2016) Amin Al-awar et al. Journal of Diabetes Research
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway
- (2015) May-Yun Wang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cardiomyocyte glucagon receptor signaling modulates outcomes in mice with experimental myocardial infarction
- (2015) Safina Ali et al. Molecular Metabolism
- SGLT2 inhibitors in the treatment of type 2 diabetes
- (2014) Farhad M. Hasan et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
- (2014) Aurora Merovci et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover
- (2012) Roger H. Unger et al. JOURNAL OF CLINICAL INVESTIGATION
- MitoNEET-driven alterations in adipocyte mitochondrial activity reveal a crucial adaptive process that preserves insulin sensitivity in obesity
- (2012) Christine M Kusminski et al. NATURE MEDICINE
- Physiologic action of glucagon on liver glucose metabolism
- (2011) C. J. Ramnanan et al. DIABETES OBESITY & METABOLISM
- Discovery of Non-Glycoside Sodium-Dependent Glucose Co-Transporter 2 (SGLT2) Inhibitors by Ligand-Based Virtual Screening
- (2010) Jian-Sung Wu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin
- (2010) William L Holland et al. NATURE MEDICINE
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic Rats
- (2008) S. Han et al. DIABETES
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now